| ROPIVACAINE HYDROCHLORIDE
Classifications: local anesthetic (ester-type); Therapeutic: local anesthetic
Prototype: Procaine HCl
Pregnancy Category: B
2 mg/mL, 5 mg/mL, 7.5 mg/mL, 10 mg/mL injection
Blocks the generation and conduction of nerve impulses, probably by increasing the threshold for electrical excitability.
Local anesthetic action produces loss of sensation and motor activity in areas of the body close to the injection site.
Local and regional anesthesia, postoperative pain management, anesthesia/pain management for obstetric procedures.
Hypersensitivity to ropivacaine or any local anesthetic of the amide type; generalized septicemia, inflammation or sepsis
at the proposed injection site; cerebral spinal diseases (e.g., meningitis); heart block, hypotension, hypertension, GI
Debilitated, older adult, or acutely ill patients; arrhythmias, shock; pregnancy (category B), lactation.
Route & Dosage
Adult: Epidural 25200 mg (0.51% solution) Nerve block 5250 mg (0.5%, 0.75% solution)
Adult: Epidural 2040 mg (0.2% solution)
Postoperative Pain Management
Adult: Epidural 1220 mg/h (0.2% solution) Infiltration 2200 mg (0.20.5% solution)
- Avoid rapid injection of large volumes of ropivacaine. Incremental doses should always be used to achieve the smallest effective
dose and concentration.
- Use an infusion concentration of 2 mg/mL (0.2%) for postoperative analgesia.
- Do not use disinfecting agents containing heavy metal ions (e.g., mercury, copper, zinc, etc.) on skin insertion site or
to clean the ropivacaine container top.
- Discard continuous infusions solution after 24 h; it contains no preservatives.
- Store unopened at 20°25° C (68°77° F).
Adverse Effects (≥1%)Body as a Whole:
Pain, fever, rigors, hypoesthesia. CNS: Paresthesia
, headache, dizziness, anxiety. CV: Hypotension,
bradycardia, hypertension, tachycardia, chest pain, fetal bradycardia. GI:
Urinary retention, oliguria. Hematologic: Anemia
Additive adverse effects with other local anesthetics
130 min (average 1020 min) depending on dose/route of administration
0.58 h depending on dose/route of administration
94% protein bound. Metabolism:
In the liver by CYP1A. Elimination:
In urine. Half-Life:
Assessment & Drug Effects
- Monitor carefully cardiovascular and respiratory status throughout treatment period. Assess for hypotension and bradycardia.
- Report immediately S&S of CNS stimulation or CNS depression.
Patient & Family Education
- Report any of the following to physician immediately: restlessness, anxiety, tinnitus, blurred vision, tremors.